Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fabrizio Stocchi, Barbara Fossati & Margherita Torti. (2020) Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease. Expert Opinion on Drug Safety 19:9, pages 1155-1172.
Read now
Read now
Antonio Di Stefano, Piera Sozio, Antonio Iannitelli & Laura Serafina Cerasa. (2009) New drug delivery strategies for improved Parkinson's disease therapy. Expert Opinion on Drug Delivery 6:4, pages 389-404.
Read now
Read now
Miguel Coelho, Joaquim Ferreira, Mário Rosa & Cristina Sampaio. (2008) Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opinion on Pharmacotherapy 9:4, pages 523-535.
Read now
Read now
Dag Nyholm & Hans Lennernäs. (2008) Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opinion on Drug Metabolism & Toxicology 4:2, pages 193-203.
Read now
Read now
Articles from other publishers (22)
Imane Frouni, Cynthia Kwan, Sébastien Belliveau & Philippe Huot. 2022. Cognition in Parkinson's Disease. Cognition in Parkinson's Disease
373
403
.
Iryna Karaban, Nina Karasevych & Tetyana Hasiuk. (2021) Prospects of successful treatment of Parkinson's disease
using apomorphine. Ageing & Longevity:4 2021, pages 1-26.
Crossref
Crossref
I.M. Karaban, N.V. Karasevych & T.V. Hasiuk. (2021) Prospects for successful treatment of Parkinson’s disease with the use of apomorphine. INTERNATIONAL NEUROLOGICAL JOURNAL 17:4, pages 54-73.
Crossref
Crossref
Kevin Ita. 2020. Transdermal Drug Delivery. Transdermal Drug Delivery
123
141
.
Pedro Merino. 2019. Chemical Biology of Neurodegeneration. Chemical Biology of Neurodegeneration
325
357
.
Margherita Torti, Daniele Bravi, Laura Vacca & Fabrizio Stocchi. (2019) Are All Dopamine Agonists Essentially the Same?. Drugs 79:7, pages 693-703.
Crossref
Crossref
Renata Ramina Pessoa, Adriana Moro, Renato Puppi Munhoz, Hélio A.G. Teive & Andrew J. Lees. (2018) Apomorphine in the treatment of Parkinson's disease: a review. Arquivos de Neuro-Psiquiatria 76:12, pages 840-848.
Crossref
Crossref
Luis Enrique Arroyo-García, Rubén Antonio Vázquez-Roque, Alfonso Díaz, Samuel Treviño, Fidel De La Cruz, Gonzalo Flores & Antonio Rodríguez-Moreno. (2018) The Effects of Non-selective Dopamine Receptor Activation by Apomorphine in the Mouse Hippocampus. Molecular Neurobiology 55:11, pages 8625-8636.
Crossref
Crossref
Yeşim Güzey Aras & Türkan Acar. (2018) İleri Evre Parkinson Hastalığında Subkutan Apomorfin Klinik Deneyimlerimiz. Sakarya Medical Journal 8:2, pages 254-259.
Crossref
Crossref
M. Auffret, S. Drapier, M. Vérin & P. Sauleau. (2016) Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue pharmacologique. Pratique Neurologique - FMC 7:1, pages 25-32.
Crossref
Crossref
Masahiro Nomoto, Shin-ichiro Kubo, Masahiro Nagai, Tatsuo Yamada, Akira Tamaoka, Yoshio Tsuboi & Nobutaka Hattori. (2015) A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease. Clinical Neuropharmacology 38:6, pages 241-247.
Crossref
Crossref
Olivier Rascol, Santiago Perez-Lloret & Joaquim J Ferreira. (2015) New treatments for levodopa-induced motor complications. Movement Disorders 30:11, pages 1451-1460.
Crossref
Crossref
Nobutaka Hattori & Masahiro Nomoto. (2014) Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease. Parkinsonism & Related Disorders 20:8, pages 819-823.
Crossref
Crossref
S. Perez-Lloret. (2013) Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease: an old drug revisited. European Journal of Neurology, pages n/a-n/a.
Crossref
Crossref
Andrzej Bogucki. (2013) Apomorfina w zaawansowanej chorobie Parkinsona. Neurologia i Neurochirurgia Polska 47:5, pages 476-483.
Crossref
Crossref
Madhav Thambisetty, Kathy A Gallardo, Jeih-San Liow, Lori L Beason-Held, John C Umhau, Abesh K Bhattacharjee, Margaret Der, Peter Herscovitch, Judith L Rapoport & Stanley I Rapoport. (2011)
The Utility of
11
C-Arachidonate PET to Study
in vivo
Dopaminergic Neurotransmission in Humans
. Journal of Cerebral Blood Flow & Metabolism 32:4, pages 676-684.
Crossref
Crossref
Marcus Malo, Lars Brive, Kristina Luthman & Peder Svensson. (2012)
Investigation of D
1
Receptor-Agonist Interactions and D
1
/D
2
Agonist Selectivity Using a Combination of Pharmacophore and Receptor Homology Modeling
. ChemMedChem 7:3, pages 483-494.
Crossref
Crossref
Rüdiger Hilker, Angelo Antonini & Per Odin. (2010) What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. Journal of Neural Transmission 118:6, pages 907-914.
Crossref
Crossref
Marcus Malo, Lars Brive, Kristina Luthman & Peder Svensson. (2010)
Selective Pharmacophore Models of Dopamine D
1
and D
2
Full Agonists Based on Extended Pharmacophore Features
. ChemMedChem 5:2, pages 232-246.
Crossref
Crossref
Andrzej Bogucki & Jarosław Sławek. (2010) Ciągła stymulacja dopaminergiczna – doświadczenia kliniczne. Neurologia i Neurochirurgia Polska 44:4, pages 385-395.
Crossref
Crossref
A. Lucotti, M. Casella, M. Tommasini, F. Gramatica, E. Di Fabrizio & G. Zerbi. (2009) Experimental and theoretical investigation of the apomorphine Raman spectrum. Journal of Raman Spectroscopy 40:12, pages 2074-2079.
Crossref
Crossref
Liming Luan, Feng Ding, Yi Ai, Anders Andersen, Peter Hardy, Eric Forman, Greg A. Gerhardt, Don M. Gash, Richard Grondin & Zhiming Zhang. (2008) Pharmacological MRI (phMRI) Monitoring of Treatment in Hemiparkinsonian Rhesus Monkeys. Cell Transplantation 17:4, pages 417-425.
Crossref
Crossref